Back to homepage

Immunology

Pharmacological treatment of COVID-19: lights and shadows

Authors: Francesco Menzella MD, Mirella Biava Msc, Chiara Barbieri MD, Francesco Livrieri MD, Nicola Facciolongo MD

The aim of this review is to explore COVID-19 treatment options and describe the potential benefits or disadvantages of their use in severe cases.

More▸

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Authors: Sonam Puri MD, Michael Shafique MD

This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade in non-small-cell lung cancer (NSCLC).

More▸

Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD
 More▸

Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues

Authors: Ashutosh M Shukla MD, Aparna Wagle Shukla MD

This article reviews the expanding clinical applicability of chloroquine and related drugs includes rheumatological and cardiovascular disorders (CVD), chronic kidney disease (CKD), oncology, and a variety of nonmalarial infections.

More▸

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Authors: Martina Biggioggero MD, Andrea Becciolini MD, Chiara Crotti MD, Elena Agape MD, Ennio Giulio Favalli MD

This narrative review discusses the rationale for JAK inhibition in RA, with a special focus on the role of JAK1 selective blockade and a detailed description of available data from the results of clinical trials on upadacitinib and filgotinib.

More▸